X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
AT-527 (bemnifosbuvir) an oral nucleotide polymerase inhibitor, small molecule drug candidate, which is being evaluated for the treatment of Covid-19 infection.
Lead Product(s): Bemnifosbuvir
Therapeutic Area: Infections and Infectious Diseases Product Name: AT-527
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2024
Details:
AT-527 (bemnifosbuvir) targets the SARS-CoV-2 RNA polymerase (nsp12), a highly conserved gene which is responsible for both replication and transcription of SARS-CoV-2. It is under phase 3 clinical trials for the treatment of COVID-19 Infection.
Lead Product(s): Bemnifosbuvir
Therapeutic Area: Infections and Infectious Diseases Product Name: AT-527
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2024
Details:
AT-527 (bemnifosbuvir) is a nucleotide polymerase inhibitor, targets the SARS-CoV-2 RNA polymerase (nsp12), a highly conserved gene that is unlikely to change as the virus mutates and vRuzasvir (RZR), an oral NS5A inhibitor for Treatment of Hepatitis C.
Lead Product(s): Bemnifosbuvir,Ruzasvir
Therapeutic Area: Infections and Infectious Diseases Product Name: AT-527
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2023
Details:
AT-527 (bemnifosbuvir) is a nucleotide polymerase inhibitor, targets the SARS-CoV-2 RNA polymerase (nsp12), a highly conserved gene that is unlikely to change as the virus mutates and variants continue to emerge.
Lead Product(s): Bemnifosbuvir
Therapeutic Area: Infections and Infectious Diseases Product Name: AT-527
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2023
Details:
AT-527 (bemnifosbuvir) is designed to inhibit viral replication by impairing viral RNA polymerase, a key component in the replication machinery of enveloped positive single-stranded RNA viruses, such as human coronaviruses and human flaviviruses.
Lead Product(s): Bemnifosbuvir
Therapeutic Area: Infections and Infectious Diseases Product Name: AT-527
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2023
Details:
Under the terms of the agreement, Atea will develop, manufacture and commercialize AT-038 (ruzasvir), an oral NS5A inhibitor, in combination with AT-527 (bemnifosbuvir) as a pan-genotypic regimen for the treatment of hepatitis C (HCV).
Lead Product(s): Ruzasvir,Bemnifosbuvir
Therapeutic Area: Infections and Infectious Diseases Product Name: AT-038
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Atea Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 07, 2023
Details:
AT-527 (bemnifosbuvir) is an oral direct-acting antiviral which is being studied to determine its potential to protect against disease progression, and the development of long-COVID complications.
Lead Product(s): Bemnifosbuvir
Therapeutic Area: Infections and Infectious Diseases Product Name: AT-527
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2022
Details:
Bemnifosbuvir (AT-527) targets SARS-CoV-2 RNA polymerase (nsp12), a highly conserved gene that is unlikely to change as the virus mutates and new variants continue to emerge.
Lead Product(s): Bemnifosbuvir
Therapeutic Area: Infections and Infectious Diseases Product Name: AT-527
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2022
Details:
Bemnifosbuvir demonstrated favorable overall nonclinical safety profile, including lack of reproductive and development toxicity in animal models, there were no AT-527-related effects on the fertility, reproduction, embryofetal and postnatal development in rats.
Lead Product(s): Bemnifosbuvir
Therapeutic Area: Infections and Infectious Diseases Product Name: AT-527
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2022
Details:
Based on the positive findings from Phase 2 clinical studies of AT-527 (bemnifosbuvir), Atea planning to initiate global Phase 2 outpatient trial which is designed to support anticipated combination trials.
Lead Product(s): Bemnifosbuvir
Therapeutic Area: Infections and Infectious Diseases Product Name: AT-527
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 07, 2022
Details:
Chugai, a strategic partner of Roche, updated that it will discontinue its development of AT-527 in Japan, an investigational RNA polymerase inhibitor for COVID-19. The development will be continued by Atea after the Roche announcement to terminate the partnership of joint development.
Lead Product(s): Bemnifosbuvir
Therapeutic Area: Infections and Infectious Diseases Product Name: AT-527
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Atea Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 16, 2021
Details:
Atea expanding development program to maximize AT-527’s profile for potential use in combination therapy to meet the current and future needs of COVID-19 as it transitions to endemic.
Lead Product(s): Bemnifosbuvir
Therapeutic Area: Infections and Infectious Diseases Product Name: AT-527
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2021
Details:
Upon termination, the rights and licenses granted by Atea to Roche under the strategic collaboration will be returned to Atea, and Atea will have full rights to continue the clinical development and future commercialization of AT-527 worldwide.
Lead Product(s): Bemnifosbuvir
Therapeutic Area: Infections and Infectious Diseases Product Name: AT-527
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 16, 2021
Details:
AT-527, is an oral direct-acting antiviral which is being studied to determine its potential to protect against disease progression, and the development of long-COVID complications. In the topline analysis, treatment with AT-527 did not meet the primary endpoint.
Lead Product(s): Bemnifosbuvir
Therapeutic Area: Infections and Infectious Diseases Product Name: AT-527
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2021
Details:
AT-527, a direct-acting antiviral (DAA) oral pill for the treatment of COVID-19. MEADOWSPRING, a global Phase 3 long-term follow-on study, is evaluating the impact of AT-527 on long-term sequelae of COVID-19 in patients previously enrolled in MORNINGSKY.
Lead Product(s): Bemnifosbuvir
Therapeutic Area: Infections and Infectious Diseases Product Name: AT-527
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 07, 2021
Details:
The interim analysis of the Phase 2 study included data from 70 hospitalized, high-risk patients with COVID-19 of which data from 62 patients were evaluable for virology analysis. Interim virology results indicated that AT-527 rapidly reduced viral load levels
Lead Product(s): Bemnifosbuvir
Therapeutic Area: Infections and Infectious Diseases Product Name: AT-527
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 30, 2021
Details:
In collaboration with Roche, AT-527 is currently being evaluated in the global Phase 3 MORNINGSKY trial, a global Phase 2 study for hospitalized patients with moderate COVID-19 and a Phase 2 outpatient study in patients with mild or moderate COVID-19.
Lead Product(s): Bemnifosbuvir
Therapeutic Area: Infections and Infectious Diseases Product Name: RO7496998
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 16, 2021
Details:
AT-527 is an orally administered, direct-acting antiviral in development and derived from Atea’s purine nucleotide prodrug platform. Trial will evaluate efficacy and safety of AT-527 for treatment of patients with mild to moderate COVID-19 in outpatient setting.
Lead Product(s): Bemnifosbuvir
Therapeutic Area: Infections and Infectious Diseases Product Name: AT-527
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2021
Details:
The study results showed AT-527 was well tolerated with a favorable safety profile. AT-527 550 mg BID led to fast attainment of steady-state levels of AT-273 within two days of dosing.
Lead Product(s): Bemnifosbuvir
Therapeutic Area: Infections and Infectious Diseases Product Name: AT-527
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2021
Details:
Under a strategic collaboration, Roche and Atea are jointly developing AT-527 for the treatment of COVID-19 and Roche has the right to commercialize AT-527 outside of the United States.
Lead Product(s): Bemnifosbuvir
Therapeutic Area: Infections and Infectious Diseases Product Name: AT-527
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 19, 2021
Details:
Roche gets exclusive rights to research, develop and distribute AT-527 as an oral antiviral treatment for COVID-19 in territories outside of the United States. At-527 is currently under evaluation as a treatment for COVID-19.
Lead Product(s): Bemnifosbuvir
Therapeutic Area: Infections and Infectious Diseases Product Name: AT-527
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: $350.0 million Upfront Cash: $350.0 million
Deal Type: Collaboration October 22, 2020
Details:
Janet has extensive experience with infectious and respiratory diseases, which should be invaluable to Atea as we move to expedite our clinical studies of AT-527 as a treatment for COVID-19.
Lead Product(s): Bemnifosbuvir
Therapeutic Area: Infections and Infectious Diseases Product Name: AT-527
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2020
Details:
Proceeds to support the clinical development of Atea’s oral, direct acting antiviral medicine for COVID-19, in addition to advancing its diverse pipeline of treatments for viral diseases.
Lead Product(s): Bemnifosbuvir
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bain Capital Life Sciences
Deal Size: $215.0 million Upfront Cash: Undisclosed
Deal Type: Series D Financing May 20, 2020
Details:
A Phase 2 clinical trial, scheduled to begin shortly, will evaluate the safety and efficacy of AT-527 in adult patients hospitalized with moderate COVID-19 disease, with one or more risk factors for poor outcomes.
Lead Product(s): Bemnifosbuvir
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 20, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
